BIO 2026: COUR Pharma last week raised a $50M series B to progress its nanoparticle approach to reprogramming the immune system to treat type 1 diabetes
- 12 minutes ago
- 1 min read
CEO Dannielle Appelhans describes how the platform works and how the company chose to focus on type 1 diabetes at this time. COUR also has partnerships with Takeda and Genentech.
Coverage brought to you by











.png)